roadtohealth, RGA partner to expand Quealth app for predictive measures

Reinsurance Group of America Incorporated (RGA) and roadtohealth are partnering up to continue development of the Quealth app, a digital health coach capable of accessing health risks.

RGA has invested $4 million in roadtohealth to develop its Quealth app. Offered across all major app stores, Quealth includes 14 years of studies of risk management information. The app is capable of assessing and presenting risk factors of five major non-communicable diseases including diabetes, cardiovascular disease, cancer, dementia and COPD.

Using question and answer tests on family history and lifestyle, which are then put through proprietary algorithms, the app calculates the users risk on a scale of 1 to 100. This “Quealth Score” then gives the user coaching on how to better manage their health based on what the biggest risks for the users are.

By not only evaluating the current state of the user but the risks that they face, Quealth works perfectly within the insurance industry. Being able to predict what might be the biggest challenges for a patient gives a heads up to the caregiver, patient and insurance. "Quealth has the credentials to make its scoring system and the inputs used to generate it relevant to our insurance business,” said Philip Smalley, MD, Senior Vice President and Chief Medical Officer of RGA International Corporation, a subsidiary of RGA. 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.